Phase 1 Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 65 years old at the time of signing consent
- You have been diagnosed with Systemic Lupus Erythematosus (SLE or Lupus) according to specific recognised medical guidelines (2019 EULAR/ACR criteria)
- Your lupus is currently active and has been confirmed through blood tests, with a disease activity score of 8 or higher on a standard measurement scale called SLEDAI 2K
- Your lupus has not responded well enough to at least 2 previous treatments, including at least one medication taken by mouth or a biologic therapy (a more advanced type of medication)
Who may not be able to join:
- You currently have lupus that is affecting your brain or mental health (sometimes called neuropsychiatric lupus)
- You have a history of certain other immune system or inflammatory conditions, such as rheumatoid arthritis, scleroderma, myositis, vasculitis, or inflammatory bowel disease — though people with stable Sjögren's syndrome, asthma, or autoimmune thyroid disease may still be considered (confirm with trial site)
- You currently have an active infection anywhere in your body, or you have a history of long-term, repeated, hidden, or recent serious infections
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Director, Climb Bio, Inc.
Phone: +1 866 857 2596
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Treatment-Emergent Adverse Events (TEAEs); Incidence of Clinical Laboratory Abnormalities; Change from Baseline in Systolic Blood Pressure; Change from Baseline in Diastolic Blood Pressure; Change from Baseline in Heart Rate; Change from Baseline in Respiratory Rate; Change from Baseline in Body Temperature; Change from Baseline in PR Interval; Change from Baseline in QRS Duration; Change from Baseline in QT Interval; Change from Baseline in QTc Interval
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.